- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06343987
The FEMA Study: Feasibility of Exercise in Patients With Metastatic Breast Cancer and Adiposity (FEMA)
Feasibility of a Physical Activity Program in Patients With Metastatic Breast Cancer and Overweight: a Randomized Controlled Trial
The goal of this clinical trial is to test a physical activity program in patients with metastatic breast cancer and overweight receiving endocrine-based treatment.
The aim of the study is to assess the feasibility and metabolic efficacy of a 12-week physical activity program in this patient group. The hypothesis is that improving metabolic health through physical activity can optimize cancer care.
Participants will randomized 2:1 to either a physical activity program or care as usual.
Study Overview
Status
Intervention / Treatment
Detailed Description
Women with overweight and obesity not only have a greater risk of developing breast cancer; they also have a worse prognosis. At diagnosis, women with overweight are more likely to have more advanced breast cancer and face an elevated risk of developing distant metastases compared to breast cancer patients with normal weight. Despite advanced disease, many patients with metastatic breast cancer live long and productive lives, but experience weight-gain, physical de-conditioning, and decreasing quality of life. On top of this, patients with endocrine-responsive metastatic breast cancer often receive treatment with aromatase inhibitors which can induce metabolic changes, increasing the risk of weight-gain and type 2 diabetes. The hypothesis is that improving metabolic health through physical activity in patients with metastatic breast cancer and overweight receiving endocrine-based treatment can optimize cancer care.
Therefore, in this randomized controlled trial, the investigators will launch a 12-week physical intervention program including 21 participants to investigate the feasibility and metabolic efficacy hereof. The program will take place at Steno Diabetes Centre Aarhus, and patients are included from the Department of Oncology, Aarhus University Hospital. The physical activity program consists of training 3 times a week with a supervising physiotherapist. Throughout the study, data will be collected through blood samples, clinical measures such as blood pressure, weight and bioimpedance, physical performance, questionnaires on quality of life, self-efficacy of cancer coping, sleep quality and feedback on the training program, and one final individual interview.
This intervention study holds significance on multiple fronts. It not only aims to enhance cancer care for our specific patient group but also to: 1) Help us understand the clinical and translational metabolic factors associated with excess weight and their impact on mental health and quality of life; 2) improve cancer care for all metastatic breast cancer patients, regardless of their weight status; and 3) potentially improve cancer care for all breast cancer patients receiving endocrine-based treatments.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Signe SB Borgquist, MD, PhD
- Phone Number: +45 22 62 45 25
- Email: signe.borgquist@auh.rm.dk
Study Contact Backup
- Name: May W Nielsen, Bsc.Med.
- Phone Number: +45 29 90 66 05
- Email: maywni@rm.dk
Study Locations
-
-
Central Denmark Region
-
Aarhus N, Central Denmark Region, Denmark, 8200
- Recruiting
- Department of Oncology, Aarhus University Hospital
-
Contact:
- Signe Borgquist, MD, PhD
- Phone Number: + 45 22 62 45 25
- Email: signe.borgquist@auh.rm.dk
-
Contact:
- May W Nielsen, Bsc.Med.
- Phone Number: +45 29 90 66 05
- Email: maywni@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosed metastatic breast cancer
- BMI ≥ 25
- Receive first-line endocrine-based therapy
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
Exclusion Criteria:
- Psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; these conditions will be discussed with the patient before registration in the trial.
- Physical health condition that either is unsafe for participation or prevents the patient from participating adequately in the physical activity program.
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention Arm
14 participants
|
12-week physical activity program with training 3 times a week.
The training consists of high-intensity training such as weight-lifting and cardiovascular training, and low-intensity training such as relaxation and stretching.
|
No Intervention: Observational Arm
7 participants
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adherence as assessed by attendance rate
Time Frame: 1 year
|
Assess adherence measured by attendance-% to the physical activity program of at least 80%.
|
1 year
|
Metabolic efficacy assessed by change in metabolic score
Time Frame: 1 year
|
Change in metabolic score calculated as the sum of Z-transformed levels of mid-blood pressure [(systolic blood pressure + diastolic blood pressure)/2], glucose, and triglycerides from baseline to end of intervention
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Perceived satisfaction assessed by qualitative interviews
Time Frame: 1 year
|
Assess the participants' satisfaction and personal experiences in the program through personal interviews, following a self-developed interview guide.
|
1 year
|
Health-related quality of life as assessed by EORTC-QLQ-30
Time Frame: 1 year
|
Change in health-related quality of life measured with European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30
|
1 year
|
Cancer coping as assessed by CBI-12
Time Frame: 1 year
|
Change in cancer coping measured with Cancer Behavior Inventory-12 (CBI-12)
|
1 year
|
Sleep quality as assessed by PSQI
Time Frame: 1 year
|
Change in sleep quality measured with Pittsburgh Sleep Quality Index (PSQI)
|
1 year
|
Insomnia as assessed by ISI
Time Frame: 1 year
|
Change in insomnia assessed by Insomnia Severity Index (ISI)
|
1 year
|
Change in C-reactive protein
Time Frame: 1 year
|
Change in circulation levels of C-reactive protein measured in mg/L
|
1 year
|
Change in leukocytes
Time Frame: 1 year
|
Change in circulation levels of total leukocytes measured in 10^9/L
|
1 year
|
Change in HbA1c
Time Frame: 1 year
|
Change in HbA1c measured in mmol/mol
|
1 year
|
Change in LDL cholesterol
Time Frame: 1 year
|
Change in LDL cholesterol measured in mmol/L
|
1 year
|
Change in HDL cholesterol
Time Frame: 1 year
|
Change in HDL cholesterol measured in mmol/L
|
1 year
|
Change in BMI
Time Frame: 1 year
|
Change in BMI kg/m^2
|
1 year
|
Fat mass
Time Frame: 1 year
|
Change in fat mass in kilogram
|
1 year
|
Muscle mass
Time Frame: 1 year
|
Change in muscle mass in kilogram
|
1 year
|
Visceral fat
Time Frame: 1 year
|
Change in visceral fat in kilogram
|
1 year
|
VO2 max
Time Frame: 1 year
|
Change in VO2 max measured by Watt-Max test
|
1 year
|
Handgrip strength
Time Frame: 1 year
|
Change in handgrip strength in kilogram measured by dynamometer after 12 weeks
|
1 year
|
Sit-rising
Time Frame: 1 year
|
Change in number of performed sit-rising in 30 seconds measured through a sitting-rising test
|
1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Signe SB Borgquist, MD, PhD, Aarhus University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1-10-72-165-23
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Breast Cancer
-
Gilead SciencesRecruitingStudy of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (ASCENT-J02)Advanced Solid Tumor | Metastatic Urothelial Cancer | Metastatic Triple-Negative Breast Cancer | HR+/HER2- Metastatic Breast CancerJapan
-
GlycoMimetics IncorporatedTerminatedBreast Cancer | Breast Cancer Metastatic | HR+ Metastatic Breast CancerUnited States
-
BriaCell Therapeutics CorporationRecruitingBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer Metastatic | End Stage CancerUnited States
-
OBI Pharma, IncCompletedMetastatic Colorectal Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Gastric CancerTaiwan
-
Massachusetts General HospitalPuma Biotechnology, Inc.; Celcuity, Inc.WithdrawnMetastatic Breast Cancer | Invasive Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast Cancer | Stage IV (Metastatic) Breast CancerUnited States
-
Novartis PharmaceuticalsCompletedMetastatic Breast Cancer | Postmenopausal Women | Locally Advanced Metastatic Breast CancerIsrael
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedMetastatic Breast Cancer | Metastatic Triple Negative Breast CancerJapan, Belgium, France, Netherlands
-
Prof. Wolfgang JanniEli Lilly and CompanyRecruitingHormone Receptor-positive Metastatic Breast Cancer | HER2-negative Metastatic Breast CancerGermany, Switzerland
-
BriaCell Therapeutics CorporationLumaBridgeEnrolling by invitationBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer MetastaticUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisDaiichi SankyoRecruitingAdvanced Breast Cancer | HER2-positive Metastatic Breast Cancer | Breast Cancer Metastatic | HER2 Low Breast CarcinomaFrance
Clinical Trials on Physical Activity
-
Health Education Research Foundation (HERF)CompletedQuality of LifePakistan
-
Zohra Institute of Health SciencesCompletedPhysical Activity and StressPakistan
-
Centre Hospitalier Universitaire DijonWithdrawn
-
Fundacion para la Investigacion y Formacion en...CompletedImpaired CognitionSpain
-
AUSL Romagna RiminiFondazione IRCCS Istituto Nazionale dei Tumori, MilanoRecruitingNon-Small Cell Lung CancerItaly
-
Fundación para la Investigación del Hospital Clínico...CompletedObesity | Severe Mental Disorder
-
Augusta UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Kansas... and other collaboratorsCompletedMental Disorders, SevereUnited States
-
Centre Hospitalier Departemental VendeeTerminated
-
Rio de Janeiro State UniversityCompleted
-
University of California, San DiegoRecruitingCognitive Change | Aging | Mild Cognitive Impairment | Cognitive Decline | Memory Disorders | Memory Impairment | Cognition Disorders in Old Age | Aging Problems | Memory Loss | Memory Disorders in Old Age | Memory Disorder, SpatialUnited States